<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02389244</url>
  </required_header>
  <id_info>
    <org_study_id>UC-0150/1309</org_study_id>
    <nct_id>NCT02389244</nct_id>
  </id_info>
  <brief_title>A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas</brief_title>
  <acronym>REGOBONE</acronym>
  <official_title>A Randomized Phase II, Placebo-controlled, Multicenter Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      INDICATION:

      Metastatic bone sarcomas: conventional high grade osteosarcoma, Ewing sarcoma of bone,
      intermediate or high-grade chondrosarcomas and chordomas
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      METHODOLOGY:

      Randomized, placebo-controlled, multicentric, phase II study -This is a double-blind
      placebo-controlled trial, with 4 cohort: cohort A: Osteosarcoma cohort B: Ewing sarcoma
      cohort C: Chondrosarcoma cohort D : chondroma. Cohort A, B and C will involve a total of 36
      patients (24 Regorafenib + 12 placebo). And cohort D a total of 24 evaluable patients (16
      Regorafenib + 8 placebo) 132 patients who meet the eligibility criteria will be randomly
      assigned in a 2:1 ratio to the following treatment groups :

      The Arm A:

      Regorafenib (160 mg/d) once daily for the 3 weeks on / 1 week off plus Best Supportive Care
      (BSC) until progression (according to RECIST 1.1), intolerance or withdrawal of consent .

      Patients receiving regorafenib who experience disease progression and for whom in the
      investigator opinion, treatment with regorafenib is providing clinical benefit, may continue
      the treatment following consultation with the study coordinator and the sponsor.

      The Arm B:

      Placebo plus BSC until progression (according to RECIST V1.1) intolerance or withdrawal of
      consent. Patients who have received placebo will receive open-label regorafenib after
      objective tumor progression.

      Patients will be stratified at randomization according to histology .
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary efficacy endpoint is progression free survival (PFS) [defined using RECIST 1.1] after central radiological review</measure>
    <time_frame>expected average duration of 3 months</time_frame>
    <description>from the date of randomization until the date of radiological progression or death whatever the cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>6 months</time_frame>
    <description>complete response (CR) or partial response (PR) according to RECIST 2009, version 1.1, for all cohorts, and CHOI criteria for chordoma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>from the date of randomization until the date of death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>the time from the date of randomization until the date of death due to any cause (up to 6 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>expected average duration of 6 months</time_frame>
    <description>objective response of CR or PR, whichever is noted earlier, to first disease progression or death before progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free rate at 3 and 6 months</measure>
    <time_frame>at 3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>from date of randomization until the date of first observation of progression (up to 6 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Growth Modulation Index defined as ratio of time to progressive disease (PD) under regorafenib to time to progression (TTP) under previous treatment</measure>
    <time_frame>time to PD under regorafenib to TTP under previous treatment (up to 6 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity according to NCI-CTCAE V4-0</measure>
    <time_frame>expected average duration of 6 months</time_frame>
    <description>according to NCI-CTCAE V4-0 (National Cancer Institut Common Terminology Criteria for Adverse Events)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain assessment using Visual analog scale (VAS), DN4 scale (Neuropathic Pain Diagnostic Questionnaire) and NPSI scale (Neuropathic Pain Symptom Inventory)</measure>
    <time_frame>expected average duration of 6 months</time_frame>
    <description>for chordomas cohort only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>from date of randomization until the date of first observation of progression (up to 6 months)</time_frame>
    <description>Progression Free Survival according to Choi criteria for Chordoma</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Ewing Sarcomas</condition>
  <condition>Chondrosarcomas</condition>
  <condition>Osteosarcomas</condition>
  <condition>Chondroma</condition>
  <arm_group>
    <arm_group_label>Regorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>160 mg/d once daily for the 3 weeks on / 1 week off plus Best Supportive Care (BSC) until progression (according to RECIST 1.1), intolerance or withdrawal of consent .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo plus BCS until progression (according to RECIST V1.1) intolerance or withdrawal of consent. Patients who have received placebo will receive open-label regorafenib after objective tumor progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regorafenib</intervention_name>
    <description>4 tablets once daily until progression or unacceptable toxicity</description>
    <arm_group_label>Regorafenib</arm_group_label>
    <other_name>Stivarga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>4 tablets once daily and switch to regorafenib after confirmed progression</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>Placebo tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must have histologically confirmed diagnosis of bone sarcoma (osteosarcoma,
             Ewing sarcoma of bone, chondrosarcoma or chordoma) ;

          2. Patients with confirmed disease progression at study entry.

          3. Metastatic disease not amenable to surgical resection or radiation with curative
             intent;

          4. Patients must have measurable disease ;

          5. Prior treatment :

             at least one, but no more than two prior chemotherapy regimen for metastatic disease
             for osteosarcoma, chondrosarcoma and Ewing sarcoma; neo-adjuvant /maintenance therapy
             are not counted towards this requirement. Chordoma not pretreated or with 1 or 2 prior
             (combination) chemotherapy regimen or with one or two prior molecularly targeted
             therapy, but no more than 2 prior lines of treatment (whatever the indication) can be
             included. At least 4 weeks since last chemotherapy (6 weeks in case of nitrosoureas
             and mitomycin C), immunotherapy or any other pharmacological treatment and/or
             radiotherapy;

          6. Age ≥ 18 years;

          7. Life expectancy of greater than 3 months;

          8. ECOG (Developed by the Eastern Cooperative Oncology Group) performance status &lt; 2
             (Karnofsky ≥ 60%);

          9. Patients must have adequate bone marrow, renal, and hepatic function, as evidenced by
             the following within 7 days of study treatment initiation : normal organ function as
             defined below :

               -  Absolute neutrophil count ≥ 1.5 Giga/L

               -  Platelets ≥ 100 Giga/L

               -  Hemoglobin≥ 9 g/dL

               -  Serum creatinin ≤ 1.5 x ULN (Upper Limit of Normal)

               -  Glomerular filtration rate (GFR) ≥30 ml/min/1.73m2 according to the modified Diet
                  in Renal Disease (MDRD) abbreviated formula

               -  AST (aspartate transaminase) and ALT (alanine transaminase) ≤2.5 x ULN

               -  Bilirubin ≤1.5 X ULN

               -  Alkaline phosphatase ≤2.5 x ULN (≤5 x ULN in patient with liver involvement of
                  their cancer). If Alkaline phosphatase &gt; 2.5 ULN, hepatic isoenzymes
                  5-nucleotidase or GGT tests must be performed; hepatic isoenzymes 5-nucleotidase
                  must be within the normal range and/or GGT &lt; 1.5 x ULN

               -  lipase ≤1.5 x ULN.

               -  Spot urine must not show 1+ or more protein in urine or the patient will require
                  a repeat urine analysis. If repeat urinalysis shows 1+ protein or more, a 24-hour
                  urine collection will be required and must show total protein excretion &lt;1000
                  mg/24 hours

         10. International Normalized Ratio(INR)/ Partial Thromboplastin Time (PTT) ≤1.5 x ULN;

        Exclusion Criteria:

          1. Prior treatment with any VEGFR inhibitor;

          2. Soft tissue sarcoma;

          3. Other cancer (different histology) within 5 years prior to randomization;

          4. Major surgical procedure, open biopsy, significant trauma, within the last 28 days
             before randomization;

          5. Cardiovascular dysfunction:

               -  Left ventricular ejection fraction (LVEF) &lt; 50%

               -  Congestive heart failure (New York Heart Association [NYHA]) ≥ 2

               -  Myocardial infarction &lt;6 months before study

               -  Cardiac arrhythmias requiring therapy

               -  Uncontrolled hypertension

               -  Unstable angina or new-onset angina

          6. Arterial or venous thrombotic or embolic events such as cerebrovascular accident
             (including transient ischemic attacks), deep vein thrombosis, or pulmonary embolism
             within the last 6 months before randomization;

          7. Severe hepatic impairment (Child-Pugh C);

          8. Ongoing infection &gt; Grade 2 according to NCI-CTCAE v4.0;

          9. Known history of human immunodeficiency virus (HIV) infection;

         10. Active hepatitis B or C or chronic hepatitis B or C requiring treatment with antiviral
             therapy ;

         11. Difficulties with swallowing study tablets;

         12. Interstitial lung disease with ongoing signs and symptoms at the time of informed
             consent;

         13. Non-healing wound, non-healing ulcer, or non-healing bone fracture;

         14. Patients with evidence or history of any bleeding diathesis, irrespective of severity;

         15. Any hemorrhage or bleeding event ≥ CTCAE Grade 3 within 4 weeks prior to the start of
             study medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florence DUFFAUD, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>La Timone University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jessy DELAYE</last_name>
    <phone>33 (0)144230404</phone>
    <email>j-delaye@unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hopital Jean Monjoz</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Elsa KALBACHER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Antoine ITALIANO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14176</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Corinne DELCAMBRE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Georges Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nicolas ISAMBERT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nicolas PENEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean Yves BLAY, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>François BERTUCCI, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>La Timone University Hospital</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Florence DUFFAUD, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICM Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Didier CUPISSOL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Antoine THYSS, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pascaline BOUDOU-ROUQUETTE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sophie PIPERNO-NEUMANN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christophe PERRIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de cancerologie de l'ouest site Rene Gauducheau</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Emmanuelle BOMPAS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie Lucien Neuwirth (ICLN)</name>
      <address>
        <city>Saint Priest en Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Olivier COLLARS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christine CHEVREAU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Helene VEGAS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de cancerologie de lorraine alexis Vautrin</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Maria RIOS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Julien DOMONT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2015</study_first_submitted>
  <study_first_submitted_qc>March 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2015</study_first_posted>
  <last_update_submitted>June 21, 2016</last_update_submitted>
  <last_update_submitted_qc>June 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Osteosarcoma</mesh_term>
    <mesh_term>Sarcoma, Ewing</mesh_term>
    <mesh_term>Chondrosarcoma</mesh_term>
    <mesh_term>Chondroma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>no individual participant data is shared</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

